GTx, Inc. (Nasdaq: GTXI) announced today that at the upcoming 2013 MASCC/ISOO International Symposium on Supportive Care In Cancer in Berlin, Germany, the Company and its clinical collaborators are showcasing two poster presentations on enobosarm for the prevention and treatment of muscle wasting in cancer patients.
Additionally, the Company is sponsoring a symposium on Muscle Wasting in Non-Small Cell Lung Cancer Patients at 2:00 PM Central European Time on June 28, 2013.
MASCC/ISOO: InterContinental Convention Centre, Berlin, Germany
Sponsored Symposium: A Novel Agent for the Potential Prevention and Treatment of Muscle Wasting in Non-Small Cell Lung Cancer Patients
Location: Hall B
Time: Friday, June 28
2:00 PM – 3:30 PM
Abstract # P2-028: Randomized Trials in NSCLC Investigating the Selective Androgen Receptor Modulator (SARM) Enobosarm to Prevent and Treat Muscle Wasting: Feasibility and Characteristics of Patients at Baseline.
Lead Author: J. Crawford
Abstract # P2-030: Improved Physical Functioning is Associated with Increased Lean Body Mass (LBM): Findings From a Phase II Trial of the Selective Receptor Modulator (SARM) Enobosarm.
Lead Author: J. Crawford
Abstracts will be presented at Poster Session 2, on Friday, June 28
, at 9:30 AM CET.
GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions.
Forward-Looking Information is Subject to Risk and Uncertainty
This press release contains forward-looking statements based upon GTx’s current expectations. Forward-looking statements involve risks and uncertainties, and include, but are not limited to, statements relating to GTx’s clinical trials for enobosarm (also known as Ostarine® or GTx-024). GTx’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks (i) that GTx will not be able to commercialize its product candidates if clinical trials do not demonstrate safety and efficacy in humans; (ii) that GTx may not be able to obtain required regulatory approvals to commercialize its product candidates in a timely manner or at all; (iii) that clinical trials being conducted by GTx may not be completed on schedule, or at all, or may otherwise be suspended or terminated; or (iv) that GTx could utilize its available cash resources sooner than it currently expects and may be unable to raise capital when needed, which would force GTx to delay, reduce or eliminate its product candidate development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. GTx’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2013 contains under the heading, “Risk Factors,” a more comprehensive description of these and other risks to which GTx is subject. GTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.